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Abstract
While the process of homo-oligomer formation and disassembly into subunits represents a
common strategy to regulate protein activity, reports of proteins in which the subunit and homo-
oligomer perform independent functions are scarce. Tumorigenesis induced by the adenovirus E4-
ORF1 oncoprotein depends on its binding to a select group of cellular PDZ proteins, including
MUPP1, MAGI-1, ZO-2 and Dlg1. We report here that in cells E4-ORF1 exists as both a
monomer and trimer and that monomers specifically bind and sequester MUPP1, MAGI-1 and
ZO-2 within insoluble complexes whereas trimers specifically bind Dlg1 and promote its
translocation to the plasma membrane. This work exposes a novel strategy wherein the
oligomerization state of a protein not only determines the capacity to bind separate related targets
but also couples the interactions to different functional consequences.
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Introduction
Among human adenoviruses, adenovirus type 9 uniquely elicits mammary tumors in
experimentally infected animals. The primary oncogenic determinant of this virus is the E4
region open-reading-frame 1 (E4-ORF1) gene, which codes for a 125-residue polypeptide
possessing two separate protein-interaction elements, the C-terminal PDZ domain-binding
motif (PBM) and centrally located Domain 2 (Lee et al., 1997; Chung et al., 2007). These
two critical elements determine the capacity of E4-ORF1 to associate with the plasma
membrane and/or membrane vesicles, to activate cellular phosphatidylinositol 3-kinase
(PI3K), and to promote cellular transformation in vitro and mammary tumorigenesis in vivo
(Frese et al., 2006; Chung et al., 2007).
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While the function of Domain 2 remains poorly understood because the 70-kDa cellular
phosphoprotein targeted by this element has not yet been identified, the PBM has been
shown to mediate interactions with the five cellular multi-PDZ domain proteins MUPP1,
PATJ, MAGI-1, ZO-2 and Dlg1. Significantly, cellular transformation induced by the E6
oncoprotein of high-risk human papillomavirus (HPV) or by the Tax oncoprotein of human
T-cell leukemia virus type 1 (HTLV-1) likewise depends on a C-terminal PBM that
mediates binding to cellular PDZ proteins (Kiyono et al., 1997; Hirata et al., 2004),
including one or more targeted by E4-ORF1 (Lee et al., 1997, 2000; Glaunsinger et al.,
2000; Latorre et al., 2005). These cellular factors act as membrane-associated scaffolds to
assemble protein complexes that control fundamental processes such as protein trafficking,
cell signaling, cell polarity, cell migration and tumor suppression (Humbert et al., 2006).
Consequently, investigating interactions of E4-ORF1 with PDZ proteins promises to reveal
important new mechanisms involved in the development of human cancers.
E4-ORF1 has been shown to alter the subcellular localization of its PDZ protein targets in
one of two strikingly different ways. In a Domain 2-independent manner, E4-ORF1
sequesters MUPP1, PATJ, MAGI-1 and ZO-2 in insoluble complexes associated with
cytoplasmic membrane vesicles or triggers Dlg1 to translocate to the plasma membrane
(Glaunsinger et al., 2000; Lee et al., 2000; Latorre et al., 2005; Frese et al., 2006; Chung et
al., 2007). These two effects on localization also yield distinct functional consequences.
Evidence suggests that sequestered PDZ proteins are functionally inactivated because, in
epithelial cells, E4-ORF1-induced sequestration of the PATJ polarity protein and ZO-2,
which are critical for tight junction (TJ) biogenesis (Shin et al., 2005; Umeda et al., 2006),
disrupts the TJ barrier function and causes a loss of apicobasal polarity (Latorre et al., 2005).
In fibroblasts, sequestration of ZO-2 also blocks its tumor suppressor activity (Glaunsinger
et al., 2001). Conversely, results indicate that E4-ORF1-induced translocation of Dlg1 to the
plasma membrane activates a Dlg1 oncogenic function required for E4-ORF1 to promote
Ras-dependent PI3K stimulation (Frese et al., 2006).
Adenovirus E4-ORF1 evolved from an ancestral cellular dUTP pyrophosphatase (dUTPase)
(Weisset al., 1997). Polypeptides encoded by dUTPase genes are comparable in length to
E4-ORF1 and form homotrimeric enzymes that hydrolyse dUTP and, in so doing, prevent
detrimental incorporation of this nucleotide into replicating cellular DNA (Mol et al., 1996).
Nonetheless, E4-ORF1 and dUTPase have functionally diverged (Weiss et al., 1997). In this
paper, we present evidence indicating that, despite their functional divergence, these two
related proteins share a conserved protein fold, as well as a capacity to form homo-trimers,
though E4-ORF1 differs from dUTPase by additionally producing monomers in cells. The
existence of two different forms of E4-ORF1 led to the discovery that each has distinct
functions, with monomers specifically binding and sequestering MUPP1, MAGI-1 and ZO-2
within insoluble complexes and trimers specifically binding Dlg1 and promoting its
translocation to the plasma membrane. Therefore, E4-ORF1 employs a novel strategy to
increase protein complexity by producing monomers and trimers that bind separate related
targets and promote different functional outcomes.
Results
Predicted structural similarity with trimeric dUTPases leads to discovery that E4-ORF1
exists as a trimer and monomer in cells
Comparative modeling analyses predicted that E4-ORF1 adopts a protein fold like trimeric
dUTPase enzymes and that the only major difference between the two proteins is located at
the C terminus where a short 4-residue E4-ORF1 PBM element replaces a longer 20-residue
dUTPase peptide containing the nucleotide-binding P-loop motif (Supplementary Figure
S1). We therefore tested whether E4-ORF1 likewise forms a trimer. Extracts of 293 T cells
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expressing either 14-kDa wild-type (wt) E4-ORF1 or 16-kDa His-tagged human dUTPase
(His-dUTPase) were prepared in NETN buffer containing NP-40 detergent and analysed by
size-exclusion chromatography (SEC) with elution buffer lacking detergent. Under these
mild conditions, His-dUTPase eluted at 45-kDa, similar to the predicted 48-kDa mass of a
trimer, whereas E4-ORF1 eluted as two peaks, one at 38-kDa and a more prominent one at
13-kDa (Figure 1a), comparable to the predicted 42- and 14-kDa masses of a trimer and
monomer, respectively. This finding suggests that E4-ORF1 exists as a trimer and monomer
in cells.
In SEC analyses otherwise identical to those described above, we discovered that
preparation of cell extracts in stringent RIPA buffer containing detergents SDS,
deoxycholate (DOC), and NP-40 rather than in mild NETN buffer eliminates the larger
putative E4-ORF1 trimer peak but not the smaller monomer peak (Figure 1b, top panel).
Conversely, the smaller but not larger peak was eliminated either completely by using RIPA
buffer as the SEC elution buffer or in a dose-dependent manner by supplementing the SEC
elution buffer with DOC but not SDS, NP-40, or Triton X-100 (Figure 1b, middle and
bottom panels) (unpublished data). The fact that purified E4-ORF1 produced only the larger
peak with DOC present in the SEC elution buffer (Supplementary Figure S2) verifies
formation of bona fide homo-trimers and supports the hypothesis that E4-ORF1 and
dUTPase have related protein structures. By contrast, His-dUTPase eluted as a trimer
regardless of extract buffer stringency or DOC inclusion in the SEC elution buffer (Figure
1). These observations suggest that cell extract preparation under stringent conditions
displaces a small, unknown cellular factor required to stabilize E4-ORF1 trimers and that
DOC complements this loss when maintained at low concentrations during SEC.
A common C-terminal element stabilizes trimer formation by dUTPase and E4-ORF1
The crystal structure of human dUTPase predicts that NH2-terminal β-strand 1 (β1) from
one subunit and C-terminal β-strand 8 (β8) from an adjacent subunit mediate intermolecular
interactions that stabilize trimer formation (Mol et al., 1996). Supporting this prediction and
the hypothesis that E4-ORF1 and dUTPase adopt a related protein fold, results from SEC
analyses with deletion mutants of dUTPase (ΔC16 and ΔC20) or E4-ORF1 (ΔC5 and ΔC7)
demonstrated a requirement for β8-residues in trimer formation by both proteins (Figure 2a,
Supplementary Figures S3 and S4).
Identical experiments were conducted with four E4-ORF1 mutants having double (AAI,
VAA and AKA) or triple (AAA) alanine substitutions in β8-residues VKI (Figure 2a). In
SEC analyses, AAI and VAA eluted as trimers, whereas AKA eluted as a mixture of trimers
and monomers, reflecting a partial defect in trimer formation (Figure 2b). By contrast, AAA
eluted primarily as a monomer and, unlike VAA, failed to self-associate in a co-IP assay
(Figure 2b, Supplementary Figure S4b). These results define β8-residues VKI as a crucial
E4-ORF1 trimerization (TRI) element.
E4-ORF1 binds cooperatively to PDZ domains in Dlg1 but not MAGI-1 and MUPP1
The existence of E4-ORF1 monomers and trimers in cells might indicate that each form has
distinct functions. In this regard, oligomeric ligands that target multi-PDZ domain proteins
often bind cooperatively to two closely situated PDZ domains, termed a PDZ tandem
(Grootjans et al., 2000; Long et al., 2003). As the E4-ORF1 trimer possesses oligomeric
PBM ligands, this feature might uniquely permit a cooperative interaction with the Dlg1
PDZ1 + 2 tandem, which mediates binding to E4-ORF1 (Frese et al., 2006). Supporting this
idea, E4-ORF1 co-IP’d wt Dlg1 but not Dlg1 mutants having PDZ1 and PDZ2 dually or
individually inactivated (Supplementary Figure S5a).
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Unlike the interaction with Dlg1, E4-ORF1 does not target a PDZ tandem in other PDZ
proteins but rather binds either one PDZ domain in ZO-2 (PDZ1) and PATJ (PDZ8) or two
non-tandem PDZ domains in MUPP1 (PDZ7 and PDZ10) and MAGI-1 (PDZ1 and PDZ3)
(Glaunsinger et al., 2000, 2001; Lee et al., 2000; Latorre et al., 2005). While E4-ORF1
would not be expected to bind cooperatively to one PDZ domain, such an interaction is
feasible with two non-tandem PDZ domains. Nonetheless, in co-IP assays, wt E4-ORF1
bound HA-tagged wt MAGI-1 but not MAGI-1 having non-tandem PDZ1 and PDZ3 dually
deleted (PDZΔ1Δ3), yet retained binding to MAGI-1 having PDZ1 or PDZ3 individually
deleted (PDZΔ1 and PDZΔ3), albeit at reduced levels compared to wt MAGI-1
(Supplementary Figure S5b) (Glaunsinger et al., 2000). The amount of E4-ORF1 binding to
wt MAGI-1 equaled the sum of binding to PDZΔ1 and PDZΔ3 (Supplementary Figure
S5b), revealing non-cooperative binding to these non-tandem PDZ domains. A similar
conclusion was drawn for E4-ORF1 binding to non-tandem PDZ domains in MUPP1 (Lee et
al., 2000).
These observations led to the hypothesis that E4-ORF1 monomers mediate non-cooperative
interactions with individual PDZ domains in MUPP1, MAGI-1, ZO-2 and PATJ whereas
E4-ORF1 trimers mediate cooperative interactions with the PDZ tandem in Dlg1.
The E4-ORF1 monomer binds and sequesters MUPP1, MAGI-1 and ZO-2
Our hypothesis predicted that monomeric AAA, as well as partially TRI-defective AKA and
TRI-competent AAI and VAA, all of which retain an intact PBM element (see Figure 2a),
should display wt binding to MUPP1, PATJ, MAGI-1 and ZO-2. In co-IP assays with
epitope-tagged PDZ proteins, these predictions were affirmed for MUPP1 and MAGI-1
(Figure 3a, Supplementary Figure S6), as well as PATJ (unpublished data). All four mutants
also exhibited wt proficiency for sequestering endogenous MUPP1 and MAGI-1 within
insoluble complexes in CREF cells (Figure 3b), which do not express PATJ (Latorre et al.,
2005). By contrast, neither wt nor mutant E4-ORF1 proteins sequestered endogenous Dlg1
(Figure 3b), consistent with previous findings (Frese et al., 2006). Based on results with
AAA, we conclude that the E4-ORF1 monomer is sufficient to bind and sequester MUPP1
and MAGI-1 in cells. As will be discussed in a subsequent section, a similar conclusion was
drawn for ZO-2, despite its reduced binding to TRI element mutants.
We also directly tested whether an E4-ORF1 monomer binds the PDZ domains of MUPP1,
MAGI-1 and ZO-2. Extracts of 293 T cells expressing HA-tagged MUPP1 PDZ10 (12-kDa),
MAGI-1 PDZ1 (14-kDa), or ZO-2 PDZ1 (13-kDa) alone or in combination with 14 kDa wt
E4-ORF1 were prepared in RIPA buffer and analysed by SEC with elution buffer lacking
DOC, conditions that convert E4-ORF1 into monomers. When expressed alone, E4-ORF1
and MAGI-1 PDZ1 eluted as 12-kDa monomers, whereas MUPP1 PDZ10 and ZO-2 PDZ1
eluted as 26-kDa dimers (Figures 3c–e). When co-expressed, E4-ORF1 and each PDZ
domain co-eluted at approximately 27-kDa (Figures 3c–e), similar to the predicted 26–28-
kDa masses for heterocomplexes composed of one E4-ORF1 molecule bound to one PDZ
domain molecule. Elution sizes of MUPP1 PDZ10 and ZO-2 PDZ1 dimers seemed
unchanged by heterocomplex formation as the incorporated E4-ORF1 monomer displaced a
PDZ domain having a similar mass. By contrast, identical experiments conducted with SEC
elution buffer containing 0.1% DOC, which converts E4-ORF1 into its trimeric form,
showed that the E4-ORF1 trimer neither co-elutes with nor changes the elution size of the
same PDZ domains (Supplementary Figure S7). Thus, the E4-ORF1 monomer specifically
binds the PDZ domains of MUPP1, MAGI-1 and ZO-2.
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Two residues in the E4-ORF1 TRI element also influence PBM-mediated binding to ZO-2
and Dlg1
As only the E4-ORF1 monomer binds ZO-2 PDZ1 (see Figure 3e), we predicted that all four
TRI element mutants would bind proficiently to ZO-2. Compared to wt E4-ORF1, however,
AAI and AKA or VAA and AAA displayed either modest or moderate binding defects,
respectively, to HA-tagged ZO-2 (Figure 4a). Our hypothesis additionally predicted that
TRI-competent AAI and VAA would exhibit wt binding to Dlg1 whereas partially TRI-
defective AKA or monomeric AAA would show a reduced ability or fail to bind Dlg1,
respectively. While AKA and AAA yielded anticipated results, AAI or VAA unexpectedly
displayed a reduced capacity or failed to interact with HA-tagged Dlg1, respectively (Figure
4b). In CREF cells, TRI element mutants showed corresponding defects in sequestering
endogenous ZO-2 within insoluble complexes (Figure 3b) and in binding endogenous Dlg1
(Supplementary Figure S8). In agreement with the fact that the oncogenic potential of E4-
ORF1 depends on binding to ZO-2 and Dlg1 (Glaunsinger et al., 2001; Frese et al., 2006),
AAI and AKA or VAA and AAA also showed a reduced ability or failed, respectively, to
promote phosphorylation of the PI3K-effector protein kinase B (PKB) and focus formation
(Supplementary Figure S9).
We drew three conclusions from these unexpected results. (1) The observation that TRI-
competent VAA exhibited reduced binding to ZO-2 and failed to bind Dlg1 indicates that
the mutated KI residues function not only in E4-ORF1 trimer formation but also in
enhancing or determining the ability of the adjacent PBM (residues ATLV) (see Figure 2a)
to mediate binding to ZO-2 or Dlg1, respectively. Thus, the KI residues dually control both
TRI and PBM element activity, redefining the E4-ORF1 PBM element as the expanded six-
residue sequence KIATLV. (2) Because KI residues enhance E4-ORF1 binding to ZO-2,
this interaction was reduced for TRI-competent VAA and monomeric AAA; however, the
fact that these mutants showed comparable weak binding to ZO-2 supports the conclusion
that an E4-ORF1 monomer is sufficient to bind this protein. (3) Because KI residues are
required for E4-ORF1 to interact with Dlg1, this protein failed to bind both TRI-competent
VAA and monomeric AAA, confounding our initial attempt to show that an E4-ORF1
trimer specifically mediates this interaction.
The E4-ORF1 trimer binds Dlg1 and promotes its translocation to the plasma membrane
To evaluate the hypothesized requirement for the E4-ORF1 trimer in Dlg1 binding, we
needed to circumvent the problem of the KI residues dually controlling activities of the TRI
and PBM elements. We reasoned that duplication of this pair of residues in wt E4-ORF1,
creating insertion mutant +KI (Figure 5a), would separate the TRI and PBM elements by
providing each with its own set of KI residues. Based on this premise, we compared TRI and
Dlg1 binding by mutant +KI and related mutants additionally having substitution mutations
in the TRI element (AAI + KI, VAA + KI, AAA + KI) or PBM element (+AA) (Figure 5a).
As expected, all mutants except AAA+KI formed trimers (Figure 5a, Supplementary Figure
S10) (unpublished data). In co-IP assays with CREF cells, TRI-competent +KI, AAI+KI and
VAA+KI bound endogenous Dlg1 with wt proficiency, whereas monomeric AAA+KI, as
well as TRI-competent PBM mutant +AA, instead behaved identically to negative-control
PBM mutant IIIA (Figure 5b). Unlike Dlg1, ZO-2 failed to bind parental mutant +KI
(unpublished data), hinting that E4-ORF1 residues upstream of the expanded PBM also
control this interaction. More important, the Dlg1 binding defect of AAA+KI was specific
and caused by a failure to oligomerize because AAA+KI sequestered endogenous MAGI-1
in CREF cells (unpublished data) and fusion of AAA+KI but not PBM mutant IIIA to
dimeric GST restored Dlg1 binding to wt levels in a GST pulldown assay (Supplementary
Figure S11). In 293 T cells, wt E4-ORF1 and TRI-competent +KI and VAA+KI also
promoted GFP-Dlg1 accumulation at the plasma membrane, whereas monomeric AAA+KI
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lacked this activity, identical to negative-control empty plasmid and PBM mutant IIIA
(Supplementary Figure S12). Besides confirming that each set of KI residues in mutant +KI
contributes separately to TRI or PBM element activity, these findings importantly
demonstrate that the E4-ORF1 trimer but not monomer binds Dlg1 and promotes its
translocation to the plasma membrane.
To obtain direct evidence that an E4-ORF1 trimer binds to the Dlg1 PDZ tandem, we
expressed 22-kDa HA-tagged Dlg1 PDZ1+2 alone or in combination with 14-kDa wt E4-
ORF1 in 293 T cells and analysed cell extracts prepared in RIPA buffer by SEC with 0.1%
DOC elution buffer. When expressed alone, E4-ORF1 eluted as a 39-kDa trimer, whereas
Dlg1 PDZ1+2 eluted as broad peak having a size range consistent with a mixture of 44-kDa
dimers and 22-kDa monomers (Figure 5c). When co-expressed, both proteins co-eluted at
60-kDa, similar to the predicted 64-kDa mass for a heterocomplex composed of an E4-
ORF1 trimer bound to one Dlg1 PDZ1+2 molecule (Figure 5c). Thus, the E4-ORF1 trimer
uniquely binds to and disrupts dimers of the Dlg1 PDZ tandem. This finding, coupled with
the inability of wt E4-ORF1 to bind Dlg1 having PDZ1 or PDZ2 inactivated (Supplementary
Figure S5a) and conversely of monomeric AAA+KI to bind wt Dlg1 (Figure 5b), imply that
two of three PBM in an E4-ORF1 trimer mediate a cooperative interaction with the two PDZ
domains in a Dlg1 PDZ tandem. Results from identical SEC analyses conducted with elution
buffer lacking DOC supported this conclusion (Supplementary Figure S13).
Discussion
The tumorigenic potential of E4-ORF1 depends on a PBM that mediates binding to five
cellular PDZ proteins. Depending on the PDZ protein, these interactions result in two
different functional consequences, yet the basis for this divergence has not been determined.
Here, we presented evidence indicating that E4-ORF1 and trimeric dUTPase share a similar
protein fold and that E4-ORF1 exists not only as a trimer but also a monomer in cells
(Figures 1 and 2, Supplementary Figure S1). This information, along with data suggesting
that E4-ORF1 binds non-cooperatively to MUPP1 and MAGI-1 yet cooperatively to Dlg1
(Supplementary Figure S5) (Lee et al., 2000), led to the discovery that monomers
specifically bind and sequester MUPP1, MAGI-1 and ZO-2 (Figures 3 and 4a,
Supplementary Figure S6) whereas trimers specifically bind and promote Dlg1 to translocate
to the plasma membrane (Figure 5, Supplementary Figures S8 and S12). Considering that
E4-ORF1 interacts with Dlg1 to trigger PI3K activation (Frese et al., 2006) or with PATJ
and ZO-2 to disrupt the TJ and cell polarity (Glaunsinger et al., 2001; Latorre et al., 2005),
we conclude that E4-ORF1 monomers and trimers perform distinct functions in cells.
One question arising from this work is: How do E4-ORF1 monomers and trimers target
different cellular PDZ proteins? While the mechanism for this selectivity is not known, the
extended C-terminal arm carrying the PBM is free and more exposed in an E4-ORF1
monomer (Supplementary Figure S1) than in a trimer (Chung et al., 2007), where the arm
engages in TRI element-dependent interactions with adjacent subunits. We speculate that
monomers specifically interact with MUPP1, PATJ, MAGI-1 and ZO-2 because
unidentified critical E4-ORF1 residues only accessible in the free C-terminal arm of a
monomer selectively stabilize binding to individual PDZ domains in these proteins but not
Dlg1. Conversely, perhaps trimers specifically interact with Dlg1 because oligomeric PBM
elements synergistically stabilize otherwise weak monomer binding to individual PDZ
domains of the Dlg1 PDZ tandem whereas an inaccessibility of postulated critical E4-ORF1
residues in the trimer precludes binding to MUPP1, PATJ, MAGI-1 and ZO-2.
We found that DOC specifically induces TRI of E4-ORF1 (Figure 1b) and possibly
dimerization of the Dlg1 PDZ tandem (Figure 5c). DOC is a bile acid produced in the liver
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by oxidation of cholesterol, an important lipid of animal cells found at the plasma membrane
and internal membranes, including membrane vesicles (Raffy and Teissie, 1999).
Interestingly, cholesterol and DOC also induce homo-oligomerization of pore-forming
bacterial toxins at host cell membranes (Bhakdi et al., 1981; Forti and Menestrina, 1989;
Ramachandran et al., 2004). Perhaps under normal physiological conditions, cholesterol
likewise promotes E4-ORF1 trimer formation and thereby interactions with Dlg1 at the
plasma membrane (Frese et al., 2006).
E4-ORF1 represents one of four known proteins having subunits and oligomers that perform
separate functions. For instance, β-actin polymers that form actin filaments are fundamental
components of the cytoskeleton, whereas β-actin monomers instead augment the activity of
the BAF mammalian SWI/SNF chromatin remodeling complex (Zhao et al., 1998) or inhibit
the MAL coactivator of the SRF pathway (Miralles et al., 2003). Furthermore, monomers or
dimers of the Pit-1 transcription factor regulate expression from either the prolactin gene or
the growth hormone gene, respectively (Holloway et al., 1995), and dimers but not
monomers of the bovine papillomavirus E5 interact with the platelet-derived growth factor β
receptor (DiMaio and Mattoon, 2001). Many growth factor receptors (for example, epithelial
growth factor receptor (EGFR)) and transcription factors (for example, nuclear factor-kappa
B (NF-κB)) are not mentioned here, as such proteins function solely as homo-dimers and
hetero-dimers formed with closely related proteins. Thus, E4-ORF1 employs a rare strategy
to increase protein complexity.
In conclusion, we showed that the combined actions of the overlapping TRI and PBM
elements uniquely permit E4-ORF1 to produce two oligomeric forms that not only bind
separate targets containing the same conserved modular domain but also promote different
functional consequences. This novel, economical strategy for increasing protein complexity
makes perfect sense for viruses, which have limited coding capacities, and also may have
broader implications by exposing a new additional mechanism, besides conventional
aminoacid sequence determinants, to permit specific binding to and differential functional
regulation of modular signaling domains. As more proteins are examined for this property,
this strategy may prove more common than presently recognized.
Materials and methods
Plasmids
E4-ORF1 and human dUTPase plasmids were constructed as previously described (Chung et
al., 2007). The HA-MUPP1 PDZ10 (aa 1606–1706), HA-MAGI-1 PDZ1 (aa 431–545), or
HA-ZO-2 PDZ1 (aa 1–113) cDNA was inserted into pGW1. pGW1 encoding HA-ZO-2,
HA-MAGI-1, HA-Dlg1 or HA-Dlg1 PDZ1 2 were described (Glaunsinger et al., 2000,
2001; Frese et al., 2006).
Antibodies
E4-ORF1, MUPP1, MAGI-1, ZO-2 and SAP97/Dlg1 antisera were described (Lee et al.,
1997; Weiss et al., 1997; Glaunsinger et al., 2000, 2001; Lee et al., 2000). Antibodies to
Dlg1 (BD Transduction Laboratories, San Jose, CA, USA), HA (Covance Research
Products, Emeryville, CA, USA), and His (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were purchased, as were HRP-conjugated goat anti-rabbit IgG and goat anti-mouse
IgG (Southern Biotechnology Associates, Birmingham, AL, USA).
Cells and extracts
Transfections were performed with TransIT LT1 (Mirus Bio Corporation, Madison, WI,
USA). MLV vectors (Soneoka et al., 1995) were produced by co-transfecting 293T cells
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with pHIT60, pME-VSVG (gift from K Maruyama, DNAX Research Institute), and
pBABE-puro encoding E4-ORF1 genes. Cell extracts were prepared in RIPA buffer (50 mM
Tris–HCl, pH 8.0, 0.15 M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) or
NETN buffer (20 mM Tris–HCl, pH 8.0, 0.1 M NaCl, 1 mM EDTA, 0.5% NP-40) containing
protease and phosphatase inhibitors. Separation of extracts into soluble supernatant and
insoluble pellet fractions was done as described (Latorre et al., 2005).
Immunoprecipitations and immunoblots
These assays were conducted as described (Frese et al., 2006).
SEC chromatography
Cell extracts mixed with size markers (200-kDa β-amylase, 66-kDa bovine serum albumin,
43-kDa ovalbumin, 29-kDa carbonic anhydrase and 12.4-kDa cytochrome c (Sigma-
Aldrich)) were loaded on a Superose 6 10/300 size-exclusion column (Amersham
Biosciences, Piscataway, NJ, USA) pre-equilibrated with elution buffer (50 mM Tris–HCl,
pH 8.0, 0.15M NaCl, 10% glycerol) lacking or containing DOC. Samples were run through
the column with elution buffer using a Pharmacia LKB Biotechnology FPLC system.
Collected fractions (0.3 ml) were resolved by SDS–PAGE. Size markers were visualized by
staining with Coomassie brilliant blue.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
E4-ORF1 exists as a monomer and trimer. (a) E4-ORF1 elutes as a monomer and trimer by
SEC. 293 T cells were transfected with pGW1 encoding wt E4-ORF1 or His-dUTPase.
Extracts in NETN buffer were fractionated by SEC with elution buffer lacking detergent and
blotted with E4-ORF1 or His antibody. Fractions lacking E4-ORF1 or dUTPase signal are
not shown. Arrows mark elution peaks of size markers. (b) Stringent detergents disrupt E4-
ORF1 trimers and DOC reverses this effect. Extracts in RIPA buffer were fractionated by
SEC with elution buffer lacking or containing DOC and analyzed as described in (a).
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Figure 2.
A C-terminal element determines dUTPase and E4-ORF1 trimerization. (a) C-terminal
mutants of human dUTPase and E4-ORF1. Gray shaded regions indicate residues needed for
trimer formation. Substitution mutations are indicated in bold. E4-ORF1 PBM residues are
underlined. (b) β8 mutations abolish E4-ORF1 trimer formation. 293 T cells were
transfected with pGW1 encoding the indicated mutant E4-ORF1. Extracts in RIPA buffer
were fractionated by SEC with elution buffer containing 0.1% DOC and blotted with E4-
ORF1 antibody.
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Figure 3.
E4-ORF1 monomers bind and sequester MUPP1, MAGI-1 and ZO-2. (a) Monomeric AAA
binds MAGI-1. 293 T cells were co-transfected with pGW1 encoding HA-MAGI-1 and
either pGW1 (vector) or pGW1 encoding wt or the indicated mutant E4-ORF1. Extracts in
RIPA buffer were IP’d with HA antibody. Recovered proteins and total cell extracts (Input)
were blotted with HA or E4-ORF1 antibody. E4-ORF1 PBM mutant IIIA (see Figure 2a) is
a negative control. (b) Monomeric AAA sequesters endogenous MUPP1 and MAGI-1.
CREF cells were transduced with pBABE (vector) or pBABE encoding wt or the indicated
mutant E4-ORF1. Extracts in RIPA buffer were separated into soluble supernatant (S) and
insoluble pellet (I) fractions. Equivalent amounts of each fraction were blotted with MUPP1,
MAGI-1, ZO-2, SAP97 (Dlg1) or E4-ORF1 antibody. (c–e) E4-ORF1 monomers bind PDZ
domains of MUPP1, MAGI-1 and ZO-2. 293 T cells were transfected with pGW1 encoding
wt E4-ORF1 and/or pGW1 encoding (c) HA-MUPP1 PDZ10, (d) HA-MAGI-1 PDZ1, or (e)
HA-ZO-2 PDZ1. Extracts in RIPA buffer were fractionated by SEC with elution buffer
lacking DOC and blotted with E4-ORF1 or HA antibody.
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Figure 4.
Residues KI in the TRI element additionally control E4-ORFl binding to ZO-2 and Dlg1. (a)
E4-ORF1 TRI element mutants have trimerization (TRI)-independent defects in binding
ZO-2. 293 cells were co-transfected with pGW1 encoding HA-ZO-2 and either pGW1
(vector) or pGW1 encoding wt or the indicated mutant E4-ORF1. Extracts in RIPA buffer
were IP’d with HA antibody. Recovered proteins and total cell extracts (Input) were blotted
with HA or E4-ORF1 antibody. (b) E4-ORF1 TRI element mutants have TRI-independent
defects in binding Dlg1. Identical experiments as those described in (a) were conducted,
except pGW1 encoding HA-Dlg1 was used.
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Figure 5.
E4-ORF1 trimers bind Dlg1. (a) C-terminal sequence of E4-ORF1 mutants and their
capacities to trimerize and bind Dlg1. Results summarized from Figure 5b, Supplementary
Figure S10, or unpublished data. The TRI or expanded PBM element are gray shaded or
underlined, respectively. Inserted residues are italicized. Alanine substitutions are indicated
in bold. (b) Monomeric AAA + KI fails to bind endogenous Dlg1. CREF cells were
transduced with pBABE (vector) or pBABE encoding wt or the indicated mutant E4-ORF1.
Extracts in RIPA buffer were IP’d with E4-ORF1 antibody. Recovered proteins were blotted
with Dlg1 or E4-ORF1 antibody. Left and right panels represent two independent
experiments. (c) E4-ORF1 trimers bind the Dlg1 PDZ1 + 2 tandem. 293 T cells were
transfected with pGW1 encoding wt E4-ORF1 or HA-Dlg1 PDZ1 + 2 alone or in
combination. Extracts in RIPA buffer were fractionated by SEC with elution buffer
containing 0.1% DOC and blotted with E4-ORF1 or HA antibody.
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